IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+3.9%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$270M
AUM Growth
+$270M
(-0.36%)
Cap. Flow
+$6.7M
Cap. Flow
% of AUM
2.48%
Top 10 Holdings %
Top 10 Hldgs %
48.55%
Holding
70
New
8
Increased
19
Reduced
15
Closed
6
Top Buys
| 1 |
Biogen
BIIB
|
$7.76M |
| 2 |
Amgen
AMGN
|
$7.74M |
| 3 |
Insmed
INSM
|
$6.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$6.21M |
| 5 |
Neurocrine Biosciences
NBIX
|
$4.49M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$8.6M |
| 2 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$7.18M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
$5.83M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$5.77M |
| 5 |
Wave Life Sciences
WVE
|
$5.63M |
Sector Composition
| 1 | Healthcare | 98.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $21.4M | 7.92% | 316,284 +38,000 | +14% | +$2.57M |
|
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $15.6M | 5.78% | 85,022 +33,900 | +66% | +$6.21M |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $13.2M | 4.91% | 156,800 +53,200 | +51% | +$4.49M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $13.2M | 4.88% | 142,522 -93,000 | -39% | -$8.6M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $12.9M | 4.79% | 98,641 +25,000 | +34% | +$3.27M |
|
|
6
Amgen
AMGN
$155B
| $12.2M | 4.51% | 66,000 +42,000 | +175% | +$7.74M |
|
7
PTC Therapeutics
PTCT
$3.92B
| $11.6M | 4.32% | 259,000 +18,507 | +8% | +$832K |
|
|
STML
8
DELISTED
Stemline Therapeutics, Inc.
STML
| $11.4M | 4.23% | 744,245 -52,000 | -7% | -$797K |
|
|
9
Biogen
BIIB
$19.4B
| $9.99M | 3.7% | 42,700 +33,200 | +349% | +$7.76M |
|
10
Exelixis
EXEL
$10.1B
| $9.48M | 3.52% | 443,534 +200,000 | +82% | +$4.28M |
|
11
Illumina
ILMN
$15.8B
| $9.24M | 3.43% | 25,100 | – | – |
|
|
12
Insmed
INSM
$28.8B
| $9.11M | 3.38% | 356,600 +246,600 | +224% | +$6.3M |
|
13
Halozyme
HALO
$8.56B
| $8.16M | 3.03% | 475,633 | – | – |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.3M | 2.71% | 23,330 -8,300 | -26% | -$2.6M |
|
15
Incyte
INCY
$16.5B
| $6.71M | 2.49% | 79,000 -22,500 | -22% | -$1.91M |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $6.22M | 2.31% | 33,996 | – | – |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.51M | 2.04% | 64,284 | – | – |
|
18
Ionis Pharmaceuticals
IONS
$6.79B
| $5.32M | 1.97% | 82,781 +35,000 | +73% | +$2.25M |
|
|
GTHX
19
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $4.47M | 1.66% | 146,000 +47,518 | +48% | +$1.46M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.22M | 1.56% | 60,900 | – | – |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $4.17M | 1.54% | 187,599 -25,462 | -12% | -$565K |
|
22
Sarepta Therapeutics
SRPT
$1.78B
| $3.97M | 1.47% | 26,100 +12,300 | +89% | +$1.87M |
|
|
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.08M | 1.14% | 128,000 | – | – |
|
|
ABMD
24
DELISTED
Abiomed Inc
ABMD
| $3.05M | 1.13% | 11,700 | – | – |
|
25
Ascendis Pharma
ASND
$11.8B
| $2.97M | 1.1% | 25,800 +12,000 | +87% | +$1.38M |
|